Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Punctate keratitis
(2004): Northington ME+, Dermatol Surg 30(12 Pt 2), 1515
Xerophthalmia (6.3%)
(2004): Northington ME+, Dermatol Surg 30(12 Pt 2), 1515
Other
Anaphylactoid reactions/Anaphylaxis
(2005): Li M+, JForensicSci50(1), 169 (with lidocaine)
(1997): LeWitt PA+, Mov Disord 12(6), 1064 (localized)
Death
(2005): Li M+, JForensicSci50(1), 169 (with lidocaine)
Infections (13–19%)
Injection-site bruising
(2004): Klein AW, JAmAcadDermatol50(1), 153
(2002): Molloy F, eMedicine Journal 3(2)
(1998): Goodman G, Australas J Dermatol 39(3), 158
Injection-site burning
(2000): Karamfilov T+, Arch Dermatol 136(4), 487
Injection-site ecchymoses
(1997): Guerrissi J+, Ann Plast Surg 39(5), 447
(1990): NIH, Consensus Statement 8(8), 1
Injection-site edema
(2004): Klein AW, JAmAcadDermatol50(1), 153
(2000): Ahn KY+, Plast Reconstr Surg 105(2), 778
(2000): Wissel J+, JPainSymptomManage20(1), 44
(1997): Guerrissi J+, Ann Plast Surg 39(5), 447
Injection-site pain (2–10%)
(2006): Kranz G+, Dermatol Surg 32(7), 886
(2002): Madalinski MH+, Eur J Gastroenterol Hepatol 14(8), 853
(4 cases)
(2002): Molloy F, eMedicine Journal 3(2)
(2001): de Almeida+, Dermatol Surg 27(1), 34
(2000): Karamfilov T+, Arch Dermatol 136(4), 487
(2000): Wissel J+, JPainSymptomManage20(1), 44
(1990): NIH Consensus Statement 8(8), 1
Injection-site reactions
(2005): Cote TR+, JAmAcadDermatol53(3), 407
Pain (6–13%)
(2004): Ghazizadeh S+, Obstet Gynecol 104(5 Pt 1), 922 (mild)
(2003): Yavuzer R+, Plast Reconstr Surg 111(1), 509
(1997): Truong DD+, Mov Disord 12(5), 772
Note: An antitoxin is available in the event of overdose or
misinjection
BRETYLIUM
Trade names: Bretylate; Critifib
Indications: Ventricular tachycardia and fibrillation
Category: Antiarrhythmic class III
Half-life: 4–17 hours
Clinically important, potentially hazardous interactions
with: arsenic, ciprofloxacin, enoxacin, gatifloxacin, lomefloxacin,
moxifloxacin, norfloxacin, ofloxacin, quinolones, sparfloxacin
Reactions
Skin
Diaphoresis (